Study S002320

Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03011021
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 40
Start: 2017-01
Primary completion: 2025-06
Lead sponsor: Second Xiangya Hospital of Central South University
Conditions: Type1 Diabetes Mellitus; Autoimmune Diabetes
Interventions: DRUG:Liraglutide; BIOLOGICAL:UCB-Treg; DRUG:Insulin
Results posted: FALSE

Registered primary outcomes

Adverse effects [2 years]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026608	G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. Zoso A, PloS one	2016	Nonrandomized study	PMID 27285580 DOI	registry reference BACKGROUND:27285580
R0028263	Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Rondas D, Diabetes, obesity & metabolism	2013	Narrative review	PMID 24003936 DOI	registry reference BACKGROUND:24003936